Abstract
PURPOSE: Ambrisentan is an ETA-selective endothelin receptor antagonist (ERA) that is approved for the treatment of pulmonary arterial hypertension (PAH) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening. Ambrisentan has been shown to improve 6-minute walk distance (6MWD) in two Phase 3, 12-week, placebo-controlled studies (ARIES-1 and ARIES-2). ARIES-E is an ongoing, long term extension study of ARIES-1 and ARIES-2. Two-year, long-term data from the ARIES studies are presented.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
